Ekso Bionics Faces Delisting Notice

Ticker: EKSO · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1549084

Ekso Bionics Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyEkso Bionics Holdings, Inc. (EKSO)
Form Type8-K
Filed DateDec 13, 2024
Risk Levelhigh
Pages4
Reading Time4 min
Key Dollar Amounts$0.001, $1.00
Sentimentbearish

Sentiment: bearish

Topics: delisting, compliance, regulatory

TL;DR

Ekso Bionics got a notice about potentially being delisted. Big trouble.

AI Summary

Ekso Bionics Holdings, Inc. filed an 8-K on December 13, 2024, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is based in San Rafael, California, and was incorporated in Nevada.

Why It Matters

This filing indicates potential issues with Ekso Bionics' compliance with stock exchange listing requirements, which could impact its stock's tradability and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial stability.

Key Numbers

  • 001-37854 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 99-0367049 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Ekso Bionics Holdings, Inc. (company) — Registrant
  • Nevada (jurisdiction) — State of incorporation
  • San Rafael, California (location) — Principal Executive Offices
  • December 13, 2024 (date) — Filing date
  • December 12, 2024 (date) — Earliest event reported

FAQ

What specific listing rule or standard has Ekso Bionics Holdings, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that has not been met, only that a notice has been received regarding potential delisting or failure to satisfy a continued listing rule or standard.

What is the date of the earliest event reported in this 8-K filing?

The earliest event reported is dated December 12, 2024.

What is the company's state of incorporation?

Ekso Bionics Holdings, Inc. is incorporated in Nevada.

Where are Ekso Bionics Holdings, Inc.'s principal executive offices located?

The principal executive offices are located at 101 Glacier Point, Suite A, San Rafael, California 94901.

What is the purpose of this Form 8-K filing?

This Form 8-K is a current report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, specifically to report a notice of delisting or failure to satisfy a continued listing rule or standard.

Filing Stats: 1,124 words · 4 min read · ~4 pages · Grade level 14.4 · Accepted 2024-12-13 16:05:52

Key Financial Figures

  • $0.001 — ge on which registered Common Stock , $0.001 par value per share EKSO Nasdaq Capit
  • $1.00 — mpany's common stock had been below the $1.00 per share minimum requirement for conti

Filing Documents

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 12, 2024, Ekso Bionics Holdings, Inc. (the "Company") received a written notice (the "Notice") from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last 31 consecutive business days, the minimum bid price of the Company's common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until June 10, 2025, to regain compliance with the Minimum Bid Price Requirement. The Notice states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule 5550(a)(2) if, at any time before June 10, 2025, the closing bid price of the Company's common stock is $1.00 per share or more for a minimum of ten consecutive business days. The Notice has no immediate effect on the listing or trading of the Company's common stock. In the event the Company does not regain compliance with the Minimum Bid Price Requirement by June 10, 2025, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, the Company will be granted an additional 180 calendar days to regain compliance. If the Company does not qualify for or fails to regain compliance during t

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not purely historical regarding the Company's or its management's intentions, beliefs, expectations and strategies for the future, including statements regarding the Company's ability to regain compliance with the Minimum Bid Price Requirement, the Company's intentions to actively monitor the closing bid price of its common stock, and the Company's plans to consider implementing available options to regain compliance with the Minimum Bid Price Requirement. All forward-looking statements included in this Current Report on Form 8-K are made as of the date of this report, based on information currently available to the Company, deal with future events, are subject to various risks and uncertainties, including the risk that the Company may not meet the Minimum Bid Price Requirement by June 10, 2025 or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from the Company's current expectations are more fully described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2024, any subsequently filed Quarterly Reports on Form 10-Q, and its other reports, each as filed with the SEC. Except as required by law, the Com

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.